Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989304 | 0.96 | ENPP2 (0.43) | ENPP2 | |
| SCHEMBL3004563 | 0.95 | ENPP2 (0.40) | ENPP2 | |
| SCHEMBL3002932 | 0.94 | ENPP2 (0.45) | ENPP2 | |
| SCHEMBL2990551 | 0.93 | ENPP2 (0.40) | ENPP2 | |
| SCHEMBL13080252 | 0.93 | ENPP2 (0.40) | ENPP2 | |
| SCHEMBL3003534 | 0.92 | — | — | |
| SCHEMBL13080262 | 0.91 | KDM4E (0.39) | ENPP2 | |
| SCHEMBL13080247 | 0.91 | ENPP2 (0.43) | ENPP2 | |
| SCHEMBL3003032 | 0.89 | — | — | |
| SCHEMBL3004959 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283361-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2012-10-09 | — | — | US | disclosed |
| US-20100190745-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190745-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190745-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | ENPP2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.